Rituximab Exerts a Dual Effect in Pemphigus VulgarisRüdiger Eming, Michael Hertl, Angela Nagel et al.|Journal of Investigative Dermatology|2008Cited by 180
Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases<sup>§</sup>Michael Hertl, Sonja Wolff‐Franke, Andreas Engert et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2008Cited by 137
Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DRβ1⁎0402 tetramersChristian Veldman, Michael Hertl, Rüdiger Eming et al.|Clinical Immunology|2006Cited by 17
Empfehlungen für den Einsatz von Rituximab (anti‐CD20‐Antikörper) bei bullösen Autoimmundermatosen<sup>§</sup>Michael Hertl, Sonja Wolff‐Franke, Detlef Zillikens et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2008Cited by 1
Corrigendum to “Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DRβ1*0402 tetramers” [Clin. Immunol. 122 (2007) 330–337]Christian Veldman, Michael Hertl, Rüdiger Eming et al.|Clinical Immunology|2012Cited by 0